

U.S. DEPARTMENT OF COMMERCE PATENT & TRADEMARK OFFICE

B/O Form PTO-1390		Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) Concerning a Filing Under 35 USC 371		Attorney's Docket Number REF/SAWATZKI/878	
International Application Number PCT/E99/05878		International Filing Date 11 August 1999		U.S. Application Number 097774188	
Title of Invention CARBOHYDRATES MIXTURE		Priority Date Claimed 11 August 1998			
Applicant(s) for DO/EO/US SAWATZKI et al.					

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items under 35 USC 371:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 USC 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 USC 371.
3. ☒ This express request to begin national examination procedures (35 USC 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 USC 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed 35 USC 371(c)(2).
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation (from e-mail copy) of the International Application into English (35 USC 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 USC 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 USC 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 USC 371(c)(4)). (☒ Executed ☐ Unexecuted)
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 USC 371(c)(5)).

Items 11 to 16 below concern other document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☐ Other items or information:

Application Number (if known) 09/7774188		International Application Number PCT/EP99/05878		Attorney's Docket Number REF/SAWATZKI/878	
				Calculations	PTO USE ONLY
17. The following fees are submitted: Basic National Fee (37 CFR 1.492(a)(1)-(5)): <input checked="" type="checkbox"/> Search report has been prepared by the EPO or JPO \$860.00 <input type="checkbox"/> International Preliminary Examination Fee paid to USPTO (37 CFR 1.482) \$690.00 <input type="checkbox"/> No International Preliminary Examination Fee paid to USPTO (37 CFR 1.482) but International Search Fee paid to USPTO (37 CFR 1.445(a)(2)) \$710.00 <input type="checkbox"/> Neither International Preliminary Examination Fee (37 CFR 1.482) nor International Search Fee (37 CFR 1.445(a)(2)) paid to USPTO \$1000.00 <input type="checkbox"/> International Preliminary Examination Fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00				\$860.00	
ENTER APPROPRIATE BASIC FEE AMOUNT				\$ 860.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).					
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	12 -20 =	0	× \$18.00	\$ 0.00	
Independent Claims	1 -3 =	0	× \$80.00	\$ 0.00	
Multiple Dependent Claims (if applicable)			+ \$270.00		
TOTAL OF ABOVE CALCULATIONS				\$ 0.00	
Reduction by ½ for filing by small entity, if applicable. Verified Small Entity Statements must also be filed (Note 37 CFR 1.9, 1.27, 1.28)					
SUBTOTAL				\$ 860.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).					
TOTAL NATIONAL FEE					
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property.				\$ 40.00	
TOTAL FEES ENCLOSED				\$ 900.00	
Amount to be:				Refunded:	
				Charged:	


- a. ☒ A check in the amount of **\$900.00** to cover the fees is enclosed.
- b. ☐ Please charge my **Deposit Account Number 02-0200** in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to **Deposit Account Number 02-0200**. A duplicate copy of this sheet is enclosed.

Note: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

BACON & THOMAS, PLLC
 625 SLATERS LANE - FOURTH FLOOR
 ALEXANDRIA, VIRGINIA 223124-1176
 (703) 683-0500

Respectfully submitted,

DATE: February 6, 2001


 Richard E. Fichter
 Attorney for Applicant
 Registration Number: 26,382

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: :
: : Attention: PCT OFFICE
SAWATZKI et al. :
: :
U.S. National Phase of PCT/EP99/05878 :
: :
Entry papers filed herewith February 6, 2001 :
: :
For: CARBOHYDRATES MIXTURE :

**PRELIMINARY AMENDMENT
AND INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The present application is the U.S. national phase of international application
number PCT/EP99/05878.

Please amend the above-identified application as follows:

IN THE CLAIMS:

Claim 3, line 1, please cancel "or 2".

Claim 4, line 1, please cancel "one of claims 1 to 3" and insert - -claim 1- -.

Claim 7, line 1, please cancel "any one of the preceding claims" and insert - -
claim 1- -.

Claim 8, line 1, please cancel "any one of the preceding claims" and insert - -
claim 1- -.

Claim 9, line 1, please cancel "any one of the preceding claims" and insert - - claim 1- -.

Claim 10, line 1, please cancel "any one of the preceding claims" and insert - - claim 1- -.

Claim 11, line 2, please cancel "any one of the preceding claims" and insert - - claim 1- -.

Claim 12, lines 1 and 2, please cancel "any one of the preceding claims 1 to 10" and insert - -claim 1- -.

REMARKS

Applicants have amended the claims in order to reduce the initial filing fee by deleting the multiple dependent claims from the application. Applicants retain the right to reintroduce any subject matter canceled by the present Amendment at any time during the prosecution of this application or any further application claiming benefit of this application.

Applicants are submitting herewith a copy of the Search Report which issued on International Application No. PCT/EP99/05878, of which the present application is the U.S. national phase. All of the publications cited in the International Search Report are listed on the attached Form PTO-1449. It is Applicants' understanding that, under the procedures of the PCT, copies of the cited publications will have been supplied to the U.S. Patent Office by the International Bureau. However, the Examiner is invited to contact the undersigned attorney if additional copies are necessary or would facilitate examination of the present application.

Otherwise, the Examiner is respectfully requested to return an initialed and dated copy of the attached Form PTO-1449 to confirm that all publications listed thereon have been considered and made officially of record in the file of this application.

Applicants understand that, under the procedures of the PCT, a copy of the priority document (DE 198 36 339.7, filed 11 August 1998) will have been supplied to the U.S. Patent Office pursuant to Rule 17 of the PCT Regulations. It is therefore respectfully requested that the first Official Action in the present application contain an indication that the appropriate priority document is in the file of this application.

In view of the above amendments, an early action on the application is now in order and is most respectfully requested.

Respectfully submitted,
BACON & THOMAS, PLLC

By: 
RICHARD E. FICHTER
Registration No. 26,382

625 Slaters Lane - 4th Floor
Alexandria, Virginia 22314
Phone: (703) 683-0500
Facsimile: (703) 683-1080

REF:kdd
PA01.wpd

DATE: February 6, 2001



CARBOHYDRATE MIXTURES

DESCRIPTION

5 The invention relates to carbohydrate mixtures for dietetic foods and pharmaceuticals, dietetic and pharmaceutical compositions containing said carbohydrate mixtures, and to the use of said carbohydrate mixtures for stimulating the human large intestinal flora.

10 As is generally known, carbohydrates represent one of the essential foundations of nutrition. This is the reason why the most differing carbohydrates are admixed to the most differing foods and also to pharmaceuticals. The task of the carbohydrates therefore is primarily of the nutritive kind, and they serve as roughage respectively.

15 Carbohydrates consist of monosaccharides, and are respectively composed thereof. Depending on their polymerization degree, the carbohydrates are indicated as oligosaccharides or polysaccharides or glycans respectively. The carbohydrates thereby are present as free oligosaccharides, as well as in a
20 bonded form such as for example in glycoproteins, proteoglycans and glycolipids.

Due to the variability of the monomers forming the carbohydrates, and due to the position of the glycosidic bond and the anomeric state of the carbohydrates and their conjugates, said carbohydrates and their conjugates represent an extremely
25 heterogeneous and extensive substance class.

Carbohydrates have most differing biological functions. Thus, they influence, for example, the bacterial colonization of the large intestine, which is a prerequisite for its normal function. The microflora of the large intestine takes part in the
30 intestinal functions in a very complex manner. This influence is preponderantly exercised by the fermentation of food components, which have not been

resorbed in the small intestine. The fermentation encompasses a plurality of functions such as the further digestion of these food components, the detoxification of endogenously occurring metabolites, the synthesis of new metabolites, some of them having a very specific effect, the return resorption of bile acids, and many other processes. The normal microflora also has a health-promoting effect in that it suppresses the growth of other pathogenous microorganisms.

Bacteria, which produce lactic acid as their most important final metabolite (so-called lactic acid-producing bacteria), play an essential role as the important representatives of the normal microflora of the large intestine. Examples for this group are bacteria of the *lactobacillus* and *bifidobacterium* genus. Therefore, efforts have been undertaken for an extended period of time on ways to control the development of a lactic acid-dominant intestinal flora by means of dietetic measures. This is particularly important in cases when a normal intestinal flora is not present or not sufficiently present due to processes caused by the development such as, for example, of new born babies or due to pathogenous states such as, for example, subsequent to an enteral antibiotic therapy or another drug therapy or during and after enteral infections.

Carbohydrates are now increasingly used in food, "functional food" and pharmaceuticals under the aspect of a biological efficiency. Thus, it is, for example, known that some carbohydrates exercise a growth-promoting effect upon various species of *bifidobacteria*, but also upon *lactobacilli*. Thus, galacto oligosaccharides, for example, have a growth-promoting effect upon *lactobacillus casei*. To date, however, only very specific species of carbohydrates having determined properties are used for promoting certain biological actions.

Thus, WO 98/26787, for example, describes the use of β -glucan and compounds derived thereof for the promotion of the population of lactic acid-producing microorganisms in the gastrointestinal tracts of human beings and animals.

Mixtures may also be used, which contain further prebiotic substances, the latter not being specified in detail.

Moreover, mixtures are known from WO 96/13271, which contain various
5 oligosaccharides and polysaccharides apart from immunoglobulins. These mixtures are used as a dietetic supplement, which, with oral administration, is supposed to be active against various gastrointestinal pathogens. The saccharides used are thereby indicated as soluble dietetic fibre, whereby it concerns inulin, fructo-oligosaccharides, pectin, guar gum and mixtures thereof.

10 In EP 0 756 828 A1, fibre-containing nutrient compositions are described, which contain in addition to oligosaccharides and/or starch, soluble polysaccharides not representing starch and insoluble polysaccharides not representing starch.

15 It is the object of the present invention to provide improved carbohydrate mixtures, which may be incorporated in dietetic nutritions and pharmaceuticals, and which, in addition to their nutritive effect, also stimulate health-promoting microorganisms present in the natural flora of the large intestine.

20 This object is solved by means of carbohydrate mixtures according to the teaching of the present claims.

Thus, the carbohydrate mixtures according to the present invention, contain at least two different, essentially soluble carbohydrate components A and B, which
25 remain undigested in the gastrointestinal tract and reach the large intestine unresorbed. The carbohydrate mixtures according to the present invention may also consist exclusively of these two carbohydrate components A and B.

Carbohydrate component A thereby consists of at least one monosaccharide or
30 from at least one oligosaccharide. Oligosaccharides are thereby understood as those comprising of 2 to 7 monosaccharide units. Hence, the oligosaccharides

refer to disaccharides, trisaccharides, tetrasaccharides, pentasaccharides and hexaasaccharides. Carbohydrate component A may also be formed by a compound of two or more of the mentioned saccharides. It may therefore be comprised of only one monosaccharide or of a mixture of two or more
5 monosaccharides or of a mixture of one or more monosaccharide/s with one or more oligosaccharide/s. It may also be comprised of any arbitrary number of various monosaccharides and/or oligosaccharides of that kind.

Carbohydrate component B consists of at least one polysaccharide comprising 7
10 or more monosaccharide units. Polysaccharides are understood as those starting from heptasaccharide (e.g. heptasaccharide, oktasaccharide, nonasaccharide, decasaccharid, etc.). Carbohydrate component B, may also be comprised of only one polysaccharide of that kind or of any arbitrary number of polysaccharides of that kind.

15 Accordingly, when in the following or in the claims, a carbohydrate component A or B is mentioned, it may refer to any one of all of these variants.

Carbohydrate component A thereby represents up to 95 wt-% of the sum of
20 carbohydrate component A and carbohydrate component B ($A + B = 100$ wt-%). Carbohydrate component B represents 5 to 95 wt-% of the sum of carbohydrate component A and carbohydrate component B.

At least 80 wt-% of the carbohydrates or saccharides out of the sum of
25 carbohydrate component A and B thereby have a prebiotic effect. Preferably, at least 80 wt-% of the carbohydrates belonging to carbohydrate component A, and also at least 80 wt-% of those belonging to carbohydrate component B, have a prebiotic effect. In other words, preferably at least 80 wt-% each of the carbohydrates or saccharides out of carbohydrate components A and B, are
30 intended to reach the large intestine in an undigested (hence not resorbable in the small intestine) manner. In other words, these carbohydrates or saccharides

of carbohydrate components A and B in the gastrointestinal tract are neither resorbed and digested in the stomach nor in the small intestine, but reach the large intestine as such.

- 5 The proportion of the not prebiotically active carbohydrates or saccharides of carbohydrate components A and B therewith amounts to a maximum of 20 wt-%. These carbohydrates or saccharides refer to those, which are actually soluble, but can be excreted in an undigested form. These carbohydrates can exercise a physical effect in that they increase, for example, the volume of the *faeces* or
 10 prompt a water adsorption.

- Soluble carbohydrates in the sense of the present invention are understood as those, which form a homogenous solution in the physical sense in water, in a concentration of at least 1 g/l at room temperature (e.g. pursuant to Roempp's
 15 *Chemie Lexikon*).

- Such as it has already been stated, the inventive carbohydrate mixtures may consist exclusively of the carbohydrate components A and B or may contain them. For the assessment of the proportion determining the carbohydrate
 20 components A and B in a dietary or pharmaceutical product, the following steps are carried out:

- In a first stage, all soluble carbohydrates are extracted from the product by means of water. Fats and proteins are removed from the extract.

25

- In a second stage, the soluble carbohydrates, or the extract respectively, are digested by means of human enzymes, e.g. human amylase, human pancreatic juice or a small intestine ciliated border preparations. The thereby resulting non-digested carbohydrates (except for the *in-vivo*-resorbable monosaccharides
 30 obtained in this *in-vitro* experiment), constitute the two carbohydrate components A and B, and 80 % thereof are supposed to be prebiotically active.

A prebiotically active carbohydrate according to the present invention is understood as a carbohydrate, which reaches the large intestine undigested (and hence is not resorbable in the small intestine), and there, it selectively encourages the growth and/or the activity of one or of a restricted number of bacterial species in the intestine, and consequently promotes health. This prebiotic effect of such carbohydrates and their specific mechanisms are described in detail in "G.R. Gibson & M.B. Roberfroid, *J. Nutr.* 1995; 125: 1401 - 1412", whereto explicit reference is herewith made, and the disclosure of which is included in the present documents.

The inventive carbohydrate mixtures hence are those, wherein the carbohydrates, which are soluble and undigested in the sense described above, fulfill the herein specified criteria and constitute the carbohydrate components A and B.

Apart from these carbohydrate components A and B, other carbohydrates may be present as well. Amongst those are 1.) the actually soluble but digestible carbohydrates, which are digestible according to the above-described second stage, and 2.) the insoluble carbohydrates, which are resorbable./digestible or even not resorbable./digestible.

These carbohydrates enumerated *sub* 1.) and 2.), may be present as such in any arbitrary quantities in addition to the carbohydrate components A and B, in each case depending on the desired final product. Preferably, the insoluble carbohydrates constitute 0 to 10 wt-% of the carbohydrate mixtures.

Carbohydrate component A may, for example, consist of one or more of the following carbohydrates: β -galactooligosaccharides, α -galactooligosaccharides, fructo-oligosaccharides, fuco-oligosaccharides, manno-oligosaccharides, xylo-oligosaccharides, sialyl-oligosaccharides, N-glycoprotein oligosaccharides, O-

glycoprotein oligosaccharides, glycolipid oligosaccharides, cello-
 oligosaccharides, chitosan-oligosaccharides, chitin-oligosaccharides,
 galacturono-oligosaccharides, glucurono-oligosaccharides, β -glucan
 oligosaccharides, arabinoxylo-oligosaccharides, arabinogalacto-
 5 oligosaccharides, xylogluco-oligosaccharides, galactomanno-oligosaccharides,
 rhamno-oligosaccharides.

Carbohydrate component B may, for example, be formed of one or more of the
 following carbohydrates or saccharides:

10

Soluble carbohydrates or saccharides: fruct(os)anes/inulins, galactans,
 fucoidans, arabinans, xylans, xanthans, β -glucans, galacturonans, N-glycans, O-
 glycans, hyaluronic acids, chondroitins, xyloglucans, arabinogalactans, alginates,
 carageenanes, galactomannans, arabinoxylanes, glycolipid glycans, glycoprotein
 15 glycans, proteoglycans.

By means of a selective combination of oligosaccharides and polysaccharides,
 and consequently the simultaneous presence of carbohydrate components A and
 B, the health-promoting microorganisms in the large intestine may be promoted
 20 by an essentially higher efficiency than it would be the case with only one of said
 carbohydrate components. Thus, it is possible with the administration of the
 inventive combination, to make very rapid restitution of a normal large intestinal
 flora, to maintain same or to prophylactically prevent an alteration of the intestinal
 flora during situations of stress, and thus to influence the bacterial colonization of
 25 the large intestine in a way, which is more efficient than the one with the
 previously used carbohydrates.

According to a preferred embodiment, at least 80 wt-% of carbohydrate
 component A as well as of carbohydrate component B consist of carbohydrates,
 30 which are bifidogenous and/or which promote lactic acid bacteria. Due to such a
 combination of oligosaccharides and polysaccharides having said properties, the

growth of the lactic acid bacteria may surprisingly be promoted in an essentially stronger manner than this would be the case with oligosaccharides or polysaccharides alone. Not only lactic acid bacteria are thereby promoted, which are naturally present in the intestine, but also the growth of those is promoted -
 5 optionally even in a selective manner - which are introduced exogenously.

Apart from this indirect action via the bacteria themselves and their metabolites such as fatty acids (butyrate, propionate, etc.), pH effects and stimulation of colonocytes, direct physical effects such as peristalsis, water content, quantity of
 10 *faeces*, mechanical action upon the intestinal *mucosa* are likewise positively influenced.

Thus, the inventive carbohydrate mixtures dispose not only of a nutritive effect but also of a wide spectrum of activities. In addition to the above-described
 15 biological effects, the following may also be achieved by means of the inventive mixtures: stabilization of a natural microflora, prevention of pathogenous substances./organisms such as toxins, viruses, bacteria, fungi, transformed cells and parasites from adhering, dissolution of complexes of toxins, viruses, bacteria, fungi and other pathogens having endogenous cells, as well as their elimination
 20 from the body, and an acceleration of wound healing.

Thus, the inventive mixtures are suitable for the prophylaxis and/or the treatment of symptoms./diseases occurring in conjunction with a disturbed intestinal flora, for example, as a consequence of the association./adhesion of the mentioned
 25 substances and organisms with/on epithelia or other endogenous cells.

The carbohydrates or saccharides of carbohydrate components A and B primarily differ in size. Nevertheless, mixtures have found to be particularly efficient, wherein the carbohydrates or the saccharides of carbohydrate component A, on
 30 the one hand, and of carbohydrate component B, on the other hand, are of a different structure. This different structure may, for example, concern the

monosaccharide composition when, for example, fructans are used on the one hand, and galactans, on the other hand. This different structure may likewise concern the glycosidic bonding (e.g. α -galacto oligosaccharaides *versus* β -galacto oligosaccharaides or α -glucans (starch) *versus* β -glucans (cellulose)).

- 5 The monomer composition, as well as the glycoside bonding may have an influence on the chemical behaviour (e.g. solubility) or on the physiological behaviour (e.g. digestibility).

- 10 The core of the inventive mixtures may *inter alia* be seen in that carbohydrates of different sizes are used, which preferably and additionally belong to at least two different "classes". With an administration of such mixtures, a synergetic effect may occur relative to the prebiotic effects of the separate substance groups A and B.

- 15 Thus, the carbohydrates of component A may not belong to one substance class alone but may also be formed out of several classes (for example A: galacto-oligosaccharides plus fuco-oligosaccharides), whereas the carbohydrates of component B may equally originate from one substance class and also from several substance classes (for example B: inulins plus xylans).

20

According to a further preferred embodiment, the carbohydrate component A constitutes 95 to 60 wt-%, and in particular about 90 wt-%, and the carbohydrate component B 5 to 40 wt-%, and in particular about 10 wt-% of the carbohydrates present *in toto*.

25

Particularly efficient mixtures are those wherein at least 60 wt-%, and in particular 80 to 100 wt-% of the carbohydrates of carbohydrate component A belong to the group of the galacto-oligosaccharides, and at least 60 wt-%, and in particular 80 to 100 wt-% of the carbohydrates of carbohydrate component B belong to the group of the fructo-polysaccharides. Galacto-oligosaccharides are composed of

30 galactose residues of different glycosidic bonds, in particular at the β 1-4 and β 1-

6 position. At the reducing end, at β 1-4 of a glycosidic bond, glucose can be present. Fructo-polysaccharides, fructans, inulins and levans being part thereof, are composed of fructose residues of glycosidic bonds at the β 2-1 and β -6 position. At the reducing end, at β 2-1 of a glycosidic bond, glucose can be present.

When a range is mentioned within the scope of the present invention, said range indication will encompass and disclose at least all integral intermediate values, and even all narrower ranges embraced by the wider range. This means that for carbohydrate component A as well as for carbohydrate component B, which may both constitute 5 to 95 wt-%, that all intermediate values such as 6, 7, 8, 9... 13, 14... 25, 26, 27... 30, 31, 32, 33... 38, 39, 40, 41... 47, 48, 49, 50, 51... 59, 60, 61, 62, 63... 72, 73, 74... 79, 80, 81, 82... 87, 88, 89, 90, 91, 92, 93 and 94 wt-% are likewise covered. The same applies to the indication that at least 80 wt-% of the carbohydrates of carbohydrate component A and at least 80 wt-% of the carbohydrates of carbohydrate component B are prebiotically active or promote lactic acid bacteria and / or are bifidogenic. Thus, the term "at least 80 wt-%" designates at least all single values between 80 wt-% and 100 wt-%, and hence, for example, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 and 100 wt-%. The carbohydrate components A and B may therewith exclusively consist of such carbohydrates.

The mixing ratio between carbohydrate component A and carbohydrate component B hence is 5 to 95 wt-%, or 95 to 5 wt-% respectively, and in particular 95 to 60, or 5 to 40 wt-% respectively. Thus, at least all integral narrower ranges are disclosed as well. The weight ratio between carbohydrate component A and carbohydrate component B may therefore, for example, be 50:50, 51:49, 52:48, 53:47, 54:46, 55:45, 56:44, 57:43, 58:42, 49:41, 60:40, 61:39, 62:38, 63:37, 64:36, 65:35, 66:34, 67:33, 68:32, 69:31, 70:30, 71:29, 72:28, 73:27, 74:26, 75:25, 76:24, 77:23, 78:22, 79:21, 80:20, 81:19, 82:18,

83:17, 84:16, 85:15, 86:14, 87:13, 88:12, 89:11, 90:10, 91:9, 92:8, 93:7, 94:6, and 95:5.

The molecular weight of the polysaccharides may thereby be of some MDas, and
 5 may be extended to particular carbohydrates. Preferably, however, polysaccharide molecules are used comprising up to 100 monosaccharide units.

For the production of the inventive carbohydrate mixtures, carbohydrates and carbohydrate mixtures known to date and used in particular for the production of
 10 foods or food products can be used. It is also possible to use raw materials previously modified in a technical way. The preparation of the inventive mixtures may thereby ensue by means of a simple blending of the correspondingly selected carbohydrates or oligosaccharides with polysaccharides or the carbohydrate mixtures. The initial components must thereby be so mixed with
 15 one another that the inventive parameters are respected with the finished inventive mixtures.

As raw materials may be used reserve carbohydrates (fructans, galacto-oligosaccharides from legumes, fucoidan, α -glucane, laminarin, carragenan,
 20 mannans, galactomannans, agar), natural gum, N-glycosidic bonded carbohydrates of glycoproteins, O-glycosidic bonded carbohydrates of glycoproteins, glycans of glycolipids, enzymatically prepared carbohydrates (galacto-oligosaccharides, gluco-oligosaccharides, xylo-oligosaccharides), bacterial carbohydrates (such as xanthans), as well as oligosaccharides (galacto-oligosaccharides, gluco-oligosaccharides (from α 1-2 and α 1-3 glucose
 25 residues), xylo-oligosaccharides), as well as skeletal carbohydrates such as celluloses, hemicelluloses (arabinans, galactans), pectins and chitins may be used. The substances should preferably be of food-grade (cf. Complex Carbohydrates in Foods, British Nutrition Foundation; Chapman & Hall, London
 30 1990). It is also possible to carrying out an enzymatic modification of the raw materials by means of hydrolases (e.g. glycosidases, transglycosidases and

lipases), transferases, isomerases (e.g. aldolases and ketolases), oxidoreductases (e.g. oxidases) and reductases (e.g. glucosedehydrogenases), lyases (e.g. polysaccharide lyases) and ligases of the raw materials and products. Moreover, it is possible to carry out a technical modification of the raw materials and products, namely by means of pressure (e.g. extrusion), temperature (e.g. caramelization), organic syntheses, organic modification (e.g. carboxymethylation and peracetylation), acid and/or alkaline hydrolysis and fractionation (e.g. depending on size and/or physico-chemical parameters such as charge and hydrophobicity).

The inventive carbohydrate mixtures thereby are essentially composed of the hereinafter listed monosaccharides and of the thereof composed oligosaccharides and polysaccharides: D-glucose, D-fructose, D-galactose, D-mannose, L-fucose, D-N-acetylglucosamine, D-N-acetylgalactosamine, D-xylose, L-rhamnose, D-arabinose, D-allose, D-talose, L-idose, D-ribose, as well as monosaccharides comprising carboxyl groups such as D-galacturon acid, D-glucuron acid, D-mannuron acid and/or the methylated forms thereof such as N-acetylneuramin acid, N-glycolylneuramin acid and/or the O-acetylated forms thereof.

Moreover, these monomers and the thereupon based higher units can be modified by means of $-OSO_3H$ groups and / or $-OPO_3H$ groups.

The subject matter of the present invention is also dietetic or pharmaceutical compositions containing said inventive carbohydrate mixtures, and the use of said above-described carbohydrate mixtures for promoting the flora of the large intestine in humans. The term "promoting / promotion" represents a general term for all of the above-listed biological actions. Thereto belongs in particular the promotion of the growth of lactic acid-producing bacteria.

The inventive mixtures may be present in the following products:

Formulas for prematurely born babies, formulas for maturely born babies, infant formulas, human milk fortifier, clinical nutrition (in general, the inventive mixture may replace a part or the entirety of other components in these nutritions, such as, for example, lactose, maltodextrin or starch, or may be added to the nutrition),
 5 pharmaceuticals, dietetic supplement (as sachet in drinks).

In the following, carbohydrate mixtures representing various preferred
 embodiments are described. The indications thereby refer to weight percent, if
 10 not indicated otherwise. In these examples it is stated to which carbohydrate
 components A or B the used carbohydrates belong. The carbohydrate
 component A is thereby only called "A", and carbohydrate component B only "B".

Example 1

Composition

90 % A = galacto-oligosaccharides

- 5 transgalacto-oligosaccharides, e.g. Elixor® (Company Borculo, enzymatic from lactose by means of β -galactosidase)

10 % B = inulin

- 10 Inulin, e.g. Raftiline® HP (Company Orafit, extraction from chicories, physical separation of the low-molecular oligosaccharides)

- 15 For the preparation of the transgalacto-oligosaccharides (Elixor®), lactose is treated with β -galactosidase. The lactose is thereby catalytically transformed in galacto-oligosaccharides, whereby a plurality of galacto-oligosaccharides are formed having varying chain lengths. Primarily, disaccharides and trisaccharides comprising 3 or 2 galactose units are thereby obtained.

Example 2

20

Composition

60 % A = galacto-oligosaccharides

transgalacto-oligosaccharides (enzymatic from lactose by means of β -galactosidase)

25

40 % B = inulin

Inulin, e.g. Raftiline® HP (Company Orafit, extraction from chicories, physical separation of the low-molecular oligosaccharides)

30

Example 3

Composition

90 % A = galacturon acid oligosaccharides

5 enzymatic from pectin

10 % B = xylose polysaccharides

enzymatic from xylan (vegetable hemicellulose)

10

Example 4

Composition

90 % A = fructo-oligosaccharides

15 enzymatic from inulin by means of endo-inulinase

10 % B = cellulose polysaccharides

enzymatic from cellulose by means of cellulase

20

Example 5

Composition

90 % A = galacto-oligosaccharides

25

10 % B = arabinans

enzymatic from vegetable hemicellulose

30 Example 6

Composition

55 % A = galacto-oligosaccharides

45 % B = fructo-polysaccharides

5

Example 7

Composition

10 85 % A = galacturon acid oligosaccharides

15 % B = fructo-polysaccharides

15 Example 8

Composition

90 % A = gluco-oligosaccharides

enzymatic by means of glucosyltransferase

20

10 % B = fructo-polysaccharides

Example 9

25

Composition

90 % A = fuco-oligosaccharides

enzymatic from algae fucoidan

30 10 % B = fructo-polysaccharides

Example 10

5 Composition

90 % A = galacto-oligosaccharides

10 % B = fuco-polysaccharides
enzymatic from algae fucoidan

10

Example 11

Composition

15 55 % A = galacto-oligosaccharides

α -galacto-oligosaccharides from soya

45 % B = fucto-polysaccharides (inulin)

20

Example 12

Composition

80 % A = transgalacto-oligosaccharaides

25

10 % A = galacturon acid oligosaccharides

10 % B = inulin

30

CLAIMS

1. Carbohydrate mixtures for dietetic food products and pharmaceuticals containing several carbohydrates, characterized in that
5 they contain or consist of two different, substantially soluble carbohydrate components A and B, which remain undigested in the gastrointestinal tract and enter the large intestine without being resorbed, that the carbohydrate component A is composed of at least one monosaccharide or of at least one oligosaccharide (disaccharide to
10 hexasaccharide) or of a mixture of two or of more of these saccharides, that the carbohydrate component B is composed of one polysaccharide (from heptasaccharide onwards) or of a mixture of two or of more polysaccharides, that the carbohydrate component A = 5 to 95 weight percent and the carbohydrate component B = 5 to 95 weight percent of the sum of the carbohydrate components A + B (= 100 weight percent), and that at least
15 80 weight percent of the carbohydrates / saccharides of the carbohydrate components A and B have a prebiotic effect.
- 20 2. Carbohydrate mixtures according to claim 1, characterized in that the carbohydrates / saccharides, which constitute the carbohydrate component A, have a different structure than the carbohydrates /saccharides, which constitute the carbohydrate component B.
25
3. Carbohydrate mixtures according to claim 1 or 2, characterized in that at least 80 weight percent of the carbohydrates / saccharides of the carbohydrate components A and B promote lactic acid bacteria and/or are bifidogenic.
30
4. Carbohydrate mixtures according to one of claims 1 to 3,

characterized in that the weight percent of the carbohydrate component A is higher than the weight percent of the carbohydrate component B.

- 5 5. Carbohydrate mixtures according to claim 4,
characterized in that the carbohydrate component A comprises 95 to 60 weight percent and the carbohydrate component B comprises 5 to 40 weight percent, with $A + B = 100$ weight percent.
- 10 6. Carbohydrate mixtures according to claim 5,
characterized in that the carbohydrate component A comprises about 90 weight percent and the carbohydrate component B comprises about 10 weight percent.
- 15 7. Carbohydrate mixtures according to any one of the preceding claims,
characterized in that the carbohydrates / saccharides of the carbohydrate components A and B do not have any glucose units linked at the α 1-4 and/or α 1-6 position.
- 20 8. Carbohydrate mixtures according to any one of the preceding claims,
characterized in that the carbohydrates / saccharides of the carbohydrate component B are composed of a maximum of up to 100 monosaccharide units.
- 25 9. Carbohydrate mixtures according to any one of the preceding claims,
characterized in that at least 60 weight percent and in particular 80 to 100 weight percent of the carbohydrates / saccharides of the carbohydrate component A belong to the galacto-oligosaccharide group and at least 60 weight percent and in particular 80 to 100 weight percent
30 of the carbohydrates / saccharides of the carbohydrate component B belong to the fructo-polysaccharide group.

10. Carbohydrate mixtures according to any one of the preceding claims,
characterized in that, apart from the carbohydrates /saccharides of
the carbohydrate components A and B, they contain an insoluble
5 carbohydrate or a soluble and digestible carbohydrate or a mixture of one
or more of these carbohydrates.
11. A dietetical or pharmaceutical composition containing a carbohydrate
mixture according to any one of the preceding claims.
- 10 12. The use of carbohydrate mixtures according to any one of the preceding
claims 1 to 10 for promoting the flora of the large intestine in humans, for
promoting the growth of lactic acid bacteria, for use in infant formulas or
for the production of infant formulas.
- 15

**ABSTRACT**

- A carbohydrate mixture for dietetic foods and pharmaceuticals containing several carbohydrates is provided according to the present invention. Said carbohydrate
- 5 mixture is characterized in that they contain or consist of two different, substantially soluble carbohydrate components A and B, which remain undigested in the gastrointestinal tract and enter the large intestine without being resorbed,
- 10 that said carbohydrate component A is composed of at least one monosaccharide or of at least one oligosaccharide (disaccharide to hexasaccharide) or of a mixture of two or more of these saccharides, that the carbohydrate component B is composed of a polysaccharide (from heptasaccharide onwards) or of a mixture of two or more polysaccharides,
- 15 that the carbohydrate component A = 5 to 95 wt-% and the carbohydrate component B = 5 to 95 wt-% of the sum of the carbohydrate components A + B (= 100 wt-%), and that at least 80 wt-% of the carbohydrates / saccharides of the carbohydrate components A and B have a prebiotic effect.
- 20 The inventive carbohydrate mixture have not only a nutritive effect but they also stimulate health-promoting microorganisms present in the natural flora of the large intestine.

DECLARATION FOR PATENT APPLICATION AND APPOINTMENT OF ATTORNEY

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name: I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention (Design, if applicable) entitled:

CARBOHYDRATES MIXTURE

the specification of which (check one):

- ☐ is attached hereto, or ☒ was filed on: **August 11, 1999** as PCT International Application Number: **PCT/EP99/05878**
and (if applicable) was amended on:

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in *Title 37, Code of Federal Regulations, §1.56*. I hereby claim foreign priority benefits under *Title 35, United States Code §119* of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

PRIOR FOREIGN APPLICATION(S)			PRIORITY CLAIMED	
Number	Country	Day/Month/Year Filed	Yes	No
198 36 339.7	DE	11 August 1998	X	

☐ Additional Priority Application(s) Listed on Following Page(s)

I HEREBY CLAIM THE BENEFIT UNDER TITLE 35 U.S. CODE §119(E) OF ANY U.S. PROVISIONAL APPLICATIONS LISTED BELOW.	
Application Number	Day/Month/Year Filed

☐ Additional Provisional Application(s) Listed on Following Page(s)

I hereby claim the benefit under *Title 35, United States Code, §120* of any United States application(s) or PCT international application(s) designating The United States of America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of *Title 35, United States Code, §112*, I acknowledge the duty to disclose information which is material to patentability as defined in *Title 37, Code of Federal Regulations, §1.56* which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application.

Application Number	Filing Date	Status - Patented, Pending or Abandoned

☐ Additional US/PCT Priority Application(s) listed on Following Page(s)


I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under *section 1001 of title 18 of the United States Code* and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: I (We) hereby appoint as my (our) attorneys, with full powers of substitution and revocation, to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: J. Ernest Kenney, Reg. No. 19,179; Eugene Mar, Reg. No. 25,823; Richard E. Fichter, Reg. No. 26,382; Thomas J. Moore, Reg. No. 28,974; Joseph DeBenedictis, Reg. No. 28,302; Benjamin E. Urcia, Reg. No. 33,805; and

I (we) authorize my(our) attorneys to accept and follow instructions from JAEGER UND KOSTER regarding any matter related to the preparation, examination, grant and maintenance of this application, any continuation, continuation-in-part or divisional based thereon, and any patent resulting therefrom, until I (we) or my(our) assigns withdraw this authorization in writing.

Send correspondence to: **BACON & THOMAS**
625 Slaters Lane - 4th Floor
Alexandria, VA 22314-1176

Telephone Calls to: **(703) 683-0500**

FULL NAME OF FIRST OR SOLE INVENTOR Günther SAWATZKI	CITIZENSHIP German
RESIDENCE ADDRESS Ricarda-Huch-Strasse 13 D-35516 Munzenberg, GERMANY DEX	POST OFFICE ADDRESS IS THE SAME AS RESIDENCE ADDRESS UNLESS OTHERWISE SHOWN BELOW
DATE 30.01.2001	SIGNATURE 

☒ See following page(s) for additional joint inventors.

ATTORNEY/DOCKET NO: REF/SAWATZKI/378
 CONTINUATION OF DECLARATION FOR PATENT APPLICATION AND APPOINTMENT OF ATTORNEY

Page 2

FULL NAME OF JOINT INVENTOR <u>Bernd STAHL</u>	CITIZENSHIP German
RESIDENCE ADDRESS Pfingstweidstrasse 39 D-61381 Friedrichsdorf, GERMANY <u>DEX</u>	POST OFFICE ADDRESS IS THE SAME AS RESIDENCE ADDRESS UNLESS OTHERWISE SHOWN BELOW
DATE 25.01.01	SIGNATURE <u>Bernd Stahl</u>

FULL NAME OF JOINT INVENTOR	CITIZENSHIP
RESIDENCE ADDRESS	POST OFFICE ADDRESS IS THE SAME AS RESIDENCE ADDRESS UNLESS OTHERWISE SHOWN BELOW
DATE	SIGNATURE

FULL NAME OF JOINT INVENTOR	CITIZENSHIP
RESIDENCE ADDRESS	POST OFFICE ADDRESS IS THE SAME AS RESIDENCE ADDRESS UNLESS OTHERWISE SHOWN BELOW
DATE	SIGNATURE

FULL NAME OF JOINT INVENTOR	CITIZENSHIP
RESIDENCE ADDRESS	POST OFFICE ADDRESS IS THE SAME AS RESIDENCE ADDRESS UNLESS OTHERWISE SHOWN BELOW
DATE	SIGNATURE

☐ See following pages for additional joint inventors/priority applications

(04/ALL-1998)